$CLCS - Cell Source, a biotechnology company, focused on developing cell therapy treatments based on the management of immune tolerance. The compamy’s patented Veto Cell technology is the centerpiece of treatment protocols that represent major breakthroughs in immune system management – safe and selective “tolerizing” of immune response.

Its technology addresses one of the most fundamental challenges in the field of immunology: how to tune immune response so that it tolerates specific “desirable” foreign cells and tissue while continuing to attack all other potential threats.